Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
Clinical trial NCT05613478 · RECRUITING
Trial details
- NCT number
- NCT05613478
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-01-31
- Primary completion
- 2025-11-01
- Enrollment
- 130
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.